TECOD
Desconocido
Biosafety: Biosafety assays for the diagnosis and prediction of drug related complement pathology
TECODEVELOPMENT GMBH
participó en un
H2020:
H2020-WIDESPREAD-2018-2020
The objective of this Twinning project is to significantly strengthen the research in SEMMELWEIS EGYETEM in the smart specialization area of...
2020-07-06 - 2023-08-31 | Financiado
2020-07-06 - 2023-08-31 | Financiado
immunoassays: Development of new immunoassays for the diagnosis and prediction of drug related complement patholog...
TECODEVELOPMENT GMBH
tramitó un
H2020:
H2020-MSCA-IF-2019
Infusion reactions (IRs) are complex, immune-mediated side effects, also known as hypersensitivity reactions (HSRs), that can occur upon int...
2020-03-05 - 2022-03-31 | Financiado
2020-03-05 - 2022-03-31 | Financiado
Need2immune: Personalized liposomal cancer vaccines within days by rapid formulation screening
TECODEVELOPMENT GMBH
tramitó un
H2020:
H2020-MSCA-IF-2018
Cancer immunotherapy, defined as the ability to mobilise the host’s own immune system to kill cancer, has recently within the last 5 years,...
2019-03-29 - 2021-08-31 | Financiado
2019-03-29 - 2021-08-31 | Financiado
* No se disponen de datos de la empresa actual.